In Vivo CAR-T vs CAR-T (Autoimmune) — Immunology Deal Terms Comparison
Market Analysis
In immunology, In Vivo CAR-T and CAR-T (Autoimmune) represent two of the most actively transacted modalities. At Phase 2, In Vivo CAR-T deals carry a median total deal value of $3.5B with $652M upfront, compared to $5.0B total value and $914M upfront for CAR-T (Autoimmune). The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. In Vivo CAR-T development milestones average $560M versus $820M for CAR-T (Autoimmune). Commercial milestones are $1.3B for In Vivo CAR-T and $1.8B for CAR-T (Autoimmune). Royalty rates range from 14.6%-24.3% for In Vivo CAR-T and 16.3%-27.2% for CAR-T (Autoimmune).
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do In Vivo CAR-T and CAR-T (Autoimmune) deal terms compare in immunology?
Which modality commands higher royalty rates: In Vivo CAR-T or CAR-T (Autoimmune)?
How do milestone structures differ between In Vivo CAR-T and CAR-T (Autoimmune)?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.